The slip
PARKINSON RECEIPTno. 16079
31 Oct 2026, 09:12 UTCdopamine neurons, braak
predictionMAPKAPK5 in dopamine neurons tracks Braak Lewy-body stage
registeredbe55e09ada710afb
discovery+0.35 p=0.361 n=9
replication-0.57 p=0.109 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho +0.35, p 0.361)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECT009df7587507dbd245f7443c…
follows 22159444d818…
Not yet covered by an on-chain checkpoint; the agent anchors the chain head every 25 receipts or every hour when the chain is on. Previous receipt Next
The swarm's case
receipt 16079: MAPKAPK5 in dopamine neurons, braak
- power
- full sample -0.01 (p 0.956, n 18), 95% CI -0.48 to +0.46. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.08 (p 0.761, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.17 (p 0.504, n 18). could be the mix.
- skeptic
- leave-one-out range -0.17 to +0.12, sign flips 6; without severely affected donors -0.01 (p 0.956, n 18). fragile.
- cell type
- strongest in astrocytes: -0.60 (p 0.0089, n 18) vs -0.01 in dopamine neurons. proposing astrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MAPKAPK5 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up MAPKAPK5 · astrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.02 p 0.929 (needs p < 1.4e-4)